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The apoptosis stimulating proteins of p53 (ASPP) family consists of three members, ASPP1, ASPP2 and iASPP. They bind to proteins
that are key players in controlling apoptosis (p53, Bcl-2 and RelA/p65) and cell growth (APCL, PP1). So far, the best-known function
of the ASPP family members is their ability to regulate the apoptotic function of p53 and its family members, p63 and p73.
Biochemical and genetic evidence has shown that ASPP1 and ASPP2 activate, whereas iASPP inhibits, the apoptotic but not the cell-
cycle arrest function of p53. The p53 tumour suppressor gene, one of the most frequently mutated genes in human cancer, is capable
of suppressing tumour growth through its ability to induce apoptosis or cell-cycle arrest. Thus, the ASPP family of proteins helps to
determine how cells choose to die and may therefore be a novel target for cancer therapy.
British Journal of Cancer (2007) 96, 196–200. doi:10.1038/sj.bjc.6603525 www.bjcancer.com
Published online 9 January 2007
& 2007 Cancer Research UK
Keywords: ASPP; p53; apoptosis
                                   
The recently discovered Apoptosis Stimulating Proteins of p53
(ASPP) family consists of three members, ASPP1, ASPP2 and
iASPP. The most evolutionary conserved member, iASPP, is the
inhibitory form and the only ASPP family member identified in
Caenorhabditis elegans (Bergamaschi et al, 2003b). Mammals,
including mice and humans, have evolved two additional
members, ASPP1 and ASPP2 (Samuels-Lev et al, 2001). All three
proteins share sequence similarity in their C-termini which
contain their signature sequences of Ankyrin repeats, SH3 domain
and Proline-rich region (Figure 1). Thus, ASPP also stands for
Ankyrin repeats, SH3 domain, and Proline-rich region containing
Protein. The C-terminus is the preferred binding site for ASPP
partners including p53 (Gorina and Pavletich, 1996), RelA/p65
(subunit 3 of nuclear factor-kB) (Yang et al, 1999a), Bcl-2
(Naumovski and Cleary, 1996), adenomatous polyposis coli-like
(APCL) (Nakagawa et al, 2000), Hepatitis-C core protein (Cao et al,
2004), amyloid-b-precursor protein-binding protein 1 (APPBP1)
(Chen et al, 2003), YES-associated protein-1 (YAP1) (Espanel and
Sudol, 2001), Sp1 (Ohno et al, 1997) and SAM68 (Thornton et al,
2006). The N-terminus is only conserved in the pro-apoptotic
members, ASPP1 and ASPP2.
To date, the most well-known function of the ASPP family of
proteins is their ability to regulate apoptosis mediated by p53 and
its family members, p63 and p73 (Bergamaschi et al, 2004). ASPP1
and ASPP2 enhance the ability of p53 to stimulate specifically the
expression of pro-apoptotic target genes but not genes involved
in cell-cycle arrest (Samuels-Lev et al, 2001; Bergamaschi et al,
2004), whereas iASPP inhibits p53-mediated apoptosis (Berga-
maschi et al, 2003b). This implies that iASPP can compete with
ASPP1 and ASPP2 for binding to p53, thereby inhibiting the ability
of ASPP1 and ASPP2 to stimulate the apoptotic function of p53.
The p53 tumour suppressor plays an important role in
regulating the proliferation of cells through either cell-cycle arrest
or apoptosis (Rowan et al, 1996). p53 has been shown to be lost or
mutated in over half of human cancers (http://www-p53.iarc.fr/).
In the other 50% of tumours, where wild-type p53 is intact, the
regulation of the p53 pathway is abnormal. Understanding why
p53 is unable to perform its role as a tumour suppressor in these
wild-type tumours has been the focus of extensive research. It is
hoped that restoration of the tumour suppressor and apoptotic
functions of p53 in tumours expressing wild-type p53 will enable
the development of new therapeutic strategies in the treatment of
cancer. In this review, we will focus on the recent understanding
of the biological function of the ASPP family of proteins and their
potential role in tumorigenesis.
iASPP IS A PROTO-ONCOGENE WHEREAS ASPP1 AND
ASPP2 ARE TUMOUR SUPPRESSORS
Depletion of the only homologue of the ASPP family, iASPP, in
C. elegans by RNAi specifically increased the number of apoptotic
germ cell corpses (Bergamaschi et al, 2003b). Because of this
resulting phenotype, the gene was termed ape-1 for apoptosis
enhancer-1, whose gene product is Ce-iASPP. These studies
provided the initial genetic evidence implicating iASPP as an
antiapoptotic gene. This unique phenotype further revealed that
Ce-iASPP is a key inhibitor of p53 in C. elegans as RNAi of iASPP
failed to show any effect in p53 null worms. Furthermore,
Ce-iASPP was identified as an inhibitor of p53 in a library screen
for p53 inhibitors (Lettre et al, 2004). Therefore, Ce-iASPP is one
of the most conserved inhibitors of p53 identified so far.
Unlike iASPP, ASPP2 is pro-apoptotic and is the most well-
characterised member of the ASPP family. Existing studies have
suggested that ASPP2 plays a central role in the regulation of
apoptosis and cell growth. The most compelling evidence comes
from the ASPP2 knockout mouse study (Vives et al, 2006). The
group examined the role of ASPP2 in tumorigenesis and its
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heterozygous mice lacking ASPP2 or ASPP2 and p53 alleles. ASPP2
knockout mice exhibit postnatal lethality. ASPP2 heterozygous
mice have 45% tumour incidence over their lifespans, whereas
wild-type mice have 15% tumour incidence. Compared to the
wild-type mice, the heterozygous mice develop twice as many
spontaneous lymphomas, as well as rhabdomyosarcomas and
squamous cell carcinomas. The ASPP2 heterozygous mice also
have an increased susceptibility to the onset of tumour develop-
ment in response to ionising radiation. The failure to generate
a p53 and ASPP2 double knockout mouse demonstrates that
ASPP2 and p53 deficiency are synthetic lethal. This phenotype also
suggests that, genetically, ASPP2 shares overlapping functions with
p53 in mouse development. Consistent with this, a combination of
p53 and ASPP2 heterozygosity accelerated the onset of tumour
development. The mouse model demonstrates unequivocally that
ASPP2 is a tumour suppressor that functions as an activator of the
tumour suppressor function of p53.
Biochemically, ASPP2-mediated apoptosis has been shown to be
inhibited by nuclear factor-kB and Bcl-2 family proteins, suggest-
ing that the antiapoptotic functions of these proteins result from
blocking the pro-apoptotic function of ASPP2 (Yang et al, 1999b;
Takahashi et al, 2005). The observation that ASPP2 can localise
to the mitochondria suggests that ASPP2 might play a role in
regulating apoptosis through a mitochondrial-dependent pathway
(Takahashi et al, 2005). Furthermore, treatment of wild-type and
p53 null cell lines with ASPP1 and ASPP2 antisense RNA reduces
apoptosis induced by DNA-damaging agents such as cisplatin,
etoposide and UV (Samuels-Lev et al, 2001; Bergamaschi et al,
2003b). Cell lines stably expressing iASPP have been produced
and are more resistant to apoptosis induced by cisplastin or UV
compared to the parental cell lines. In addition, co-expression of
ASPP1 and ASPP2 inhibits, whereas expression of iASPP enhances,
the transforming activity of the oncogenes RAS and E1A in rat
embryo fibroblasts, further implicating ASPP1 and ASPP2 as
tumour suppressors, whereas iASPP is likely to be a proto-
oncogene (Bergamaschi et al, 2003b).
ALTERED ASPP EXPRESSION IN HUMAN CANCERS IS
LINKED TO TUMOUR PROGRESSION
Initial evidence suggesting the involvement of ASPP in human
cancer came from the analysis of the crystal structure of the C-
terminal ankyrin repeats and SH3 domains of ASPP2 and the
DNA-binding domain of p53. The amino acids in p53 responsible
for binding to ASPP2, namely 178His, 181Arg, 243Met and 247Arg,
are all mutated to a relatively high frequency in human cancer
(Gorina and Pavletich, 1996). Importantly, the two most frequently
mutated residues, 248Arg and 273Arg, contact both DNA and
ASPP2.
Recent studies have shown altered expression of the ASPP
family members in a variety of human cancers. The expression of
ASPP1 and ASPP2 is frequently downregulated in human breast
tumours (Samuels-Lev et al, 2001) and tumour cell lines (Liu et al,
2005) expressing wild-type p53, suggesting that there is a selective
advantage for loss of ASPP1 and ASPP2 expression in human
breast tumours expressing wild-type p53. Reduced levels of ASPP2
have also been detected in human lung cancer cell lines (Mori et al,
2000), and ASPP1 downregulation was observed in one non-
small-cell lung carcinoma cell line and two mesothelioma cell lines
(Mori et al, 2004). Furthermore, in leukaemia cancer cell lines a
concomitant downregulation of ASPP1 with an upregulation of
iASPP has been observed, suggesting that abnormal ASPP
expression could be an important step in the formation of human
haematopoietic neoplasms and might be a useful molecular marker
for the diagnosis of leukaemia (Liu et al, 2004). Significantly higher
levels of iASPP were detected in human breast carcinomas
(Bergamaschi et al, 2003a), leukaemia cell lines and acute
leukaemias (AL) (Zhang et al, 2005). Interestingly, the level of
iASPP gene expression was significantly higher in AL than in
cells from normal donors or AL patients in complete remission,
suggesting that overexpression of iASPP may promote leukaemo-
genesis and/or disease progression of AL (Zhang et al, 2005).
Other studies have linked reduced ASPP2 levels with poor
prognosis and metastasis. A lowered ASPP2 expression was linked
to a poor clinical outcome in diffuse large B-cell lymphoma
(Lossos et al, 2002) and with poor distant recurrence-free survival
in breast cancer patients (Cobleigh et al, 2005). Reduced
expression of ASPP2 has also been observed in a microarray
study of metastatic breast cancer samples compared to non-
metastatic samples (Sgroi et al, 1999), suggesting that ASPP2 might
be associated with breast cancer progression. Furthermore, an
association between the ASPP2 (TP53BP2) locus and gastric
cancer susceptibility has also been reported (Ju et al, 2005). Four
single nucleotide polymorphisms (g.206692C4T, g.198267A4T,
g.164895G4A and g.152389A4T) within TP53BP2 showed a
significant link with gastric cancer susceptibility.
REGULATION OF ASPP EXPRESSION
Our current understanding is that three main mechanisms are
involved in the regulation of the ASPP family members:
inactivation and gene silencing by methylation, activation by E2F
transcription factors and regulation of ASPP2 at the protein level.
The mechanism of action and the regulation of the ASPP family
members in tumour cells is summarised in Figure 2.
ASPP1 and ASPP2 gene silencing
DNA methylation is the main epigenetic modification in humans,
and changes in the methylation status of genes play an important
role in tumorigenesis. Aberrant methylation of normally un-
methylated CpG islands in the promoters of various tumour
suppressor genes has been reported (Merlo et al, 1995). Initial
evidence for methylation-dependent regulation of ASPP2 expres-
sion came from the observation that methyl-CpG-binding protein
1 (MBD1) is required for the formation of the CAF-1/MBD1/
SETDB1 complex, which facilitates methylation during replication-
coupled chromatin assembly (Sarraf and Stancheva, 2004). In the
absence of MBD1, methylation at multiple genomic loci is lost.
This results in the activation of the ASPP2 gene, which is normally
repressed by MBD1, demonstrating that ASPP2 expression is
regulated by methylation.
Furthermore, hypermethylation of the CpG islands in the 50
untranslated regions of the ASPP1 and ASPP2 genes and reduced
expression of ASPP1 and ASPP2 is reported in HEPG-2, MCF-7
and A549 cell lines which express wild-type p53 (Liu et al, 2005).
In contrast, in normal fibroblasts, the ASPP1 and ASPP2 genes are
unmethylated. This suggests that epigenetic changes of ASPP1 and
ASPP2 occur in tumours that are wild type for p53 and that
downregulation of ASPP1 and ASPP2 expression correlates with
Pro Ank SH3  ASPP1 1091
Pro Ank  SH3 ASPP2 1128
Pro Ank SH3 828 iASPP
Figure 1 The human ASPP family structure. The amino-acid length of
each ASPP member is indicated on the right, and individual structural
elements are highlighted. Abbreviations: a, a-helical domain; Pro, proline-
rich region; Ank, ankyrin repeats; SH3, SH3 domain.
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of ASPP1 in acute lymphoblastic leukaemia (ALL) is also
significantly reduced as a consequence of the hypermethylation
of the ASPP1 gene promoter (Agirre et al, 2006). In addition,
methylation of ASPP1 is significantly higher in adult compared to
childhood ALL, and T-cell compared to B-cell ALL. Relapse rate
and mortality are significantly higher in patients expressing
methylated ASPP1. Finally, methylation of the ASPP1 gene
promoter is indicative of a poor prognosis in ALL patients.
Consistent with these findings, another study shows aberrant
methylation of ASPP1 in 34% of the 50 patients with de novo T-cell
ALL (Roman-Gomez et al, 2005).
ASPP1 and ASPP2 are transcriptional targets of E2F1
The E2F1 transcription factor is a downstream target of the tumour
suppressor retinoblastoma (Rb). When activated, E2F1 induces cell
proliferation. E2F1 can also mediate apoptosis via p53-dependent
and independent mechanisms. ASPP1 and ASPP2 have been
identified as transcriptional targets of E2F, and increased
expression of E2F-1 was shown to induce the expression of ASPP1
and ASPP2 at both mRNA and protein levels (Stanelle et al, 2002;
Chen et al, 2005; Fogal et al, 2005; Hershko et al, 2005). Many
tumour types exhibit defective Rb pathways and consequently an
increased E2F activity. As a result, they also have an increased
expression of ASPP1, ASPP2 or both, thereby enhancing the
cellular sensitivity to p53-mediated apoptosis. This may be one
possible explanation as to why tumour cells are more sensitive to
p53-dependent apoptosis than primary cells.
Regulation of ASPP2 expression at the protein level
The proteasome, a major component of the ubiquitin-mediated
protein degradation pathway, has recently become a therapeutic
target in cancer therapy. Treatment of cells with bortezomib, a
specific inhibitor of the proteasome which is clinically active in
different tumour types, increased ASPP2 protein and protein
half-life but not RNA levels (Zhu et al, 2005). Treatment with
anthracycline, a chemotherapy agent that can induce DNA damage
and inhibit the proteasome, also increased ASPP2 protein but
not RNA levels. In addition, knockdown of ASPP2 by siRNA
attenuated bortezomib-induced apoptosis in wild-type p53 cells.
Importantly, the central region of ASPP2 is ubiquitinated. Taken
together, these data demonstrate that ASPP2 is a direct proteaso-
mal substrate, and that proteasomal degradation modulates ASPP2
protein levels and apoptotic function. Furthermore, post-transla-
tional control of ASPP2 following DNA damage and stress
induction may be an important mechanism by which ASPP2
stimulates apoptosis under these conditions.
iASPP MODULATES THE APOPTOTIC FUNCTION OF
p53 CODON 72 POLYMORPHIC VARIANTS
The most common p53 polymorphism whereby either an arginine
(p53Arg72) or a proline (p53Pro72) is expressed at codon 72 only
exists in humans and p53Arg72 is human-specific. The frequency
of the allele encoding p53Pro72 is closely linked to latitude and is
much higher in populations living near the equator suggesting that
p53Pro72 is selected in an environment with high levels of UV light
(Sjalander et al, 1995). A novel mechanism by which the ASPP
family members selectively regulate the apoptotic function of
p53Pro72 and p53Arg72 has been described (Bergamaschi et al,
2006). iASPP has a higher binding affinity to p53Pro72 than to
p53Arg72, and preferentially modulates the apoptotic potential of
p53Pro72 over p53Arg72. Furthermore, p53Arg72 is more active
than p53Pro72 in the induction of apoptosis, and the greater
apoptosis inducing activity of p53Arg72 results from its ability to
escape iASPP inhibition. Thus, the most efficient way to inactivate
the apoptotic function of p53Arg72 in human tumorigenesis
is by intragenic mutation. An alternative way to inactivate the
p53Pro72 isoform is by reduced expression of ASPP1, ASPP2 or
overexpression of iASPP in addition to mutation in p53 itself.
Therefore, the ASPP family provides an additional level of
regulation of p53. This work suggests that the expression levels
of the ASPP family members taken together with the expression of
polymorphic p53 variants can provide clues about cancer




















Figure 2 Regulation of ASPP family of proteins. Stress signals including DNA damage, upregulation of the E2F transcription factors and inhibition of the
proteasome activate ASPP1 and ASPP2 to interact with p53 family members and induce apoptosis. iASPP prevents this, instead allowing cell proliferation to
occur. Gene silencing of ASPP1 and ASPP2 by methylation also prevents p53-dependent apoptosis.
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Inactivation of ASPP1 and ASPP2, proteins that cooperate with p53
to induce apoptosis, and activation of the inhibitor of p53, iASPP,
appear to be common themes in human tumours and are linked
to poor prognosis and metastasis. Reduced expression of ASPP1
and ASPP2, or increased expression of iASPP, appear to be
mechanisms involved in preventing wild-type p53 from working
effectively. Hence, the ASPP family of proteins may be novel
prognostic markers for human cancers. Identification of molecules
that target the altered expression of the ASPP family members,
whereby ASPP1 and ASPP2 expression could be enhanced or
iASPP expression reduced, will allow us to develop new therapeutic
strategies to treat cancer. For instance, a nine amino-acid peptide
derived from ASPP2 (CBP3) was found to bind to the p53 core
domain and stabilise it in vitro (Friedler et al, 2002). CBP3 was
capable of restoring the apoptotic function of mutant p53, thereby
killing mutant p53-expressing cells. From a chemical library
screen, a small molecule, RITA (reactivation of p53 and induction
of tumour cell apoptosis ), was identified, which bound to p53 and
induced its accumulation in tumour cells (Issaeva et al, 2004).
RITA was shown to disrupt the interaction between p53 and
MDM2, and was able to reactivate p53 in tumours that have
aberrant MDM2 expression. The compound was also able to
inhibit the interaction between iASPP and p53 and hence induce
apoptosis.
The role of ASPP1, ASPP2 and iASPP in exerting positive and
negative effects on the activity of p53 needs to be further explored
in a tissue- and cell-type context. The altered expression of p53
activators such as ASPP1 and ASPP2 and inhibitors of p53 such as
iASPP during tumour development in different tissue and cell
types may explain the variation in p53 mutation rates in different
tumour types. Furthermore, by taking into account both ASPP
expression pattern and p53 codon 72 polymorphism, specific
chemotherapeutic regimes could be tailored to different tumour
types and individual patients.
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